Spotlight – KRS: A cut away from release in exosomes

JCB

KRS: A cut away from release in exosomes

 
Catherine Rabouille

Cancer cells often trigger an inflammatory process, which in some cases may be driven by the presence of lysyl-tRNA synthetase (KRS) in the medium. Kim et al. (2017. J. Cell Biol.https://doi.org/10.1083/jcb.201605118) now demonstrate that cleavage of the KRS by caspase-8 inside cells triggers its interaction with syntenin and its release in inflammatory exosomes.

Aminoacyl-tRNA synthetases (ARSs) are intriguing enzymes. Intracellularly, they catalyze the covalent attachment of amino acids to tRNAs and are key regulators of protein translation. However, these housekeeping enzymes have many other tricks up their sleeves. In the cell, several ARSs are also able to regulate gene expression at the level of transcription, splicing, and translation but via noncatalytic and unique mechanisms. ARSs also have different functions in the extracellular space, where they can elicit cytokine signaling responses that control angiogenesis, induce immune and proinflammatory gene expression programs, and trigger cell migration or apoptosis. The response elicited by particular ARSs is specific to the target cells (Son et al., 2014). For instance, when present in the extracellular medium, lysyl-tRNA synthetase (KRS) binds to macrophages and monocytes and activates MAPK signaling pathways that induce macrophage migration and TNF production (Park et al., 2005). How ARSs are released to the extracellular medium to carry out these activities is unknown. ARSs do not contain a signal peptide, and pharmacological agents blocking secretion through the secretory pathway have no effect on the amount of ARS in the medium. For a while, the presence of ARSs in the extracellular medium was thus thought to be caused by their passive release from cells that have undergone necrosis. In this issue, Kim et al. reinvestigate how KRS is released from cancer cells and find that this occurs through a caspase-8– and syntenin-dependent incorporation of KRS in exosomes.

http://jcb.rupress.org/content/early/2017/06/15/jcb.201706039

Related Post

Collaboration work with Scripps and Hebrew Univers...
views 339
Biocon collaborated with Dr. Min Guo (Scripps), and Dr. Ehud Razin (Hebrew University) to investigate KRS. They together published an article about KR...
전세계 신약후보물질 수집하는 中 바이오제약사...
views 132
(바이오스펙테이터=장종원기자) 기사입력 : 2018-07-12 15:48|수정 : 2018-07-12 15:48 중국 바이오제약기업들이 전세계 신약 후보물질을 공격적으로 인수하고 있다. 막대한 자금을 앞세워 상대적으로 부족한 신약 파이프라인을 강화하기 위한...
ARS research comes to Gordon Research Conference
views 362
Biocon의 주력 타겟군인 ARS (aminoacyl-tRNA synthetase)들과 translation, disease, cure들의 주제가 Gordon Research Conference 주제로 선정이 되어 2015년부터 2년 간격으로 개최가 될 예정입니다.현...
Biocon 조성호 팀장 , 2018 한국컴퓨터종합학술대회 우수논문상 선정...
views 667
Biocon 조성호 정보팀장이 "웹 기반 초고속 신약 후보물질 탐색-계산 시스템 구현"이란 제목으로 제출한 논문이  6월 21일 개최되는 '2018 한국컴퓨터종합학술대회(KCC2018)'에서 우수논문상으로 선정되었습니다. 조성호 팀장은 "몇 달 동안 주말을...

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2010-2018 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?

Skip to toolbar